Unicycive Therapeutics Inc. (UNCY) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Unicycive Therapeutics Inc. (NASDAQ: UNCY) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $3.74 (-1.84% 1D, market cap $106.1M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, UNCY ranks #414 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), UNCY carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, OKUR (OnKure Therapeutics Inc. (Class A)) holds a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $106.1M) and IMUX (Immunic Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $106.4M). Among the 5-stock peer group, UNCY leads on earnings multiple (N/A) while ORGO leads on capital efficiency (17.1% ROIC).
Per UNCY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001766140), Unicycive Therapeutics Inc. generated $0 in revenue, -$26.6M in net income, and -$31.3M in free cash flow against $49.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 7% of 52W Range • RSI-14 at 40.5 (NEUTRAL RANGE)
20D Institutional Volume Accumulation (±12.5% realized swing band)
Capital intensity & 0% operating margin leave 16 pts on the table
While UNCY currently carries a cautious 45/100 (D) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.54) and Max Pain ($3.93) forces dealer call-delta covering toward $9.18.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Unicycive Therapeutics Inc. (UNCY) slipped -1.84% to $3.74, trading at 7% of its 52-week range ($3.35 – $8.74). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Unicycive Therapeutics Inc. (UNCY) market action, institutional positioning, and fundamental catalysts.
Morningstar report covering Unicycive Therapeutics Inc. (UNCY) market action, institutional positioning, and fundamental catalysts.
Zacks Investment Research report covering Unicycive Therapeutics Inc. (UNCY) market action, institutional positioning, and fundamental catalysts.
Moomoo report covering Unicycive Therapeutics Inc. (UNCY) market action, institutional positioning, and fundamental catalysts.
Stocktwits report covering Unicycive Therapeutics Inc. (UNCY) market action, institutional positioning, and fundamental catalysts.
The National Law Review report covering Unicycive Therapeutics Inc. (UNCY) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Unicycive Therapeutics Inc. (UNCY) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Unicycive Therapeutics Inc. (UNCY) market action, institutional positioning, and fundamental catalysts.
Unicycive Therapeutics is rated Buy, with a risk-adjusted fair value of $6.97 per share, nearly 95% upside from current prices. Read more on UNCY stock here.
Resubmission includes Chemistry, Manufacturing, and Controls (CMC) data from new drug product (DP) manufacturing vendorMountain View, California – Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ:UNCY)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on UNCY today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for UNCY. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Unicycive Therapeutics Inc. (UNCY) ranks #414 by composite RQD confidence (45/100, grade D) and #653 by equity capitalization ($106.1M). Within this direct 5-issuer industry benchmark cohort, UNCY leads on earnings valuation at N/A trailing P/E, while ORGO leads on capital efficiency and profitability with 17.1% ROIC and — gross margin. ORGO currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with UNCY at 45/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| UNCY
ACTIVE
Unicycive Therapeutics Inc. | D | 45/100 | — | — | -35.0% | -1.84% | $106.1M | Benchmark Subject |
| OKUR OnKure Therapeutics Inc. (Class A) | D | 46/100 | — | — | -35.0% | 0.00% | $106.1M | /okur-vs-uncy → |
| IMUX Immunic Inc. | D- | 38/100 | — | — | -35.0% | -3.66% | $106.4M | /imux-vs-uncy → |
| ORGO Organogenesis Holdings Inc. (Class A) | D | 50/100 | — | — | 17.1% | -6.20% | $105.4M | /orgo-vs-uncy → |
| NERV Minerva Neurosciences Inc | D- | 38/100 | — | — | -35.0% | +3.57% | $107.0M | /nerv-vs-uncy → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Unicycive Therapeutics Inc. (UNCY) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 , and -100.0% cumulative change since FY2023) , GAAP net income of -$26.6M, operating cash flow of -$31.3M, and free cash flow of -$31.3M (-9.4% YoY). On the balance sheet, UNCY closed FY2025 with $49.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$26.6M | -$31.3M | -$31.3M | $49.1M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$36.7M | -$28.6M | -$28.6M | $31.7M | — |
| FY2023 (FY) | 2023-12-31 | $675.0K | -$30.5M | -$18.3M | -$18.3M | — | — |
As of 2026-11-02, Unicycive Therapeutics Inc. (NASDAQ: UNCY) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $3.74 (-1.84% 1D, market cap $106.1M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, UNCY ranks #414 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), UNCY carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, OKUR (OnKure Therapeutics Inc. (Class A)) holds a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $106.1M) and IMUX (Immunic Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $106.4M). Among the 5-stock peer group, UNCY leads on earnings multiple (N/A) while ORGO leads on capital efficiency (17.1% ROIC).
Per UNCY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001766140), Unicycive Therapeutics Inc. generated $0 in revenue, -$26.6M in net income, and -$31.3M in free cash flow against $49.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
UNCY last traded at $3.74 (-1.84% on volume of 1,300,302 shares), positioning the stock -17.62% below its 50-day simple moving average ($4.54) and -38.69% below its 200-day simple moving average ($6.10). Across its 52-week range of $3.35 to $8.74, UNCY sits at the 7.2% percentile with a 14-day RSI of 40.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.27 to $4.21).
Why UNCY Stock slipped -1.84% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
The Roarable RQD Score is 45 out of 100, graded D, with the verdict "Roarable Sell — Underperform / Distribution Warning" (per the Roarable RQD rating). The five pillars are:
For a prospective investor, the practical implication is that the score is driven by the absence of earnings and cash generation rather than by leverage. The balance sheet pillar is middling rather than weak, and the macro pillar is moderate. Upside would depend on operating results improving faster than the current cash-burn profile suggests, which the source data does not evidence. The valuation tradeoff is that a $106.1M market capitalization is being carried without positive earnings or free cash flow, so the price rests on future outcomes not captured in these sources. This is an analytical reading of the rating, not personalized advice.
Unicycive Therapeutics Inc. (UNCY) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry (per the company profile). The profile identifies a market capitalization of $0.1B. The source data does not describe the company's products, customers, or revenue model. Revenue is reported as $0.0M in FY 2025 and FY 2024 (per the SEC financials), indicating no meaningful commercial revenue in those periods.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-29.5M | $-26.6M | N/A | $-31.3M | $29.2M | N/A |
| FY 2024 | $0.0M | $-32.1M | $-36.7M | N/A | $-28.6M | $26.1M | N/A |
| FY 2023 | $0.7M | $-20.8M | $-30.5M | N/A | $-18.3M | N/A | N/A |
Profitability is negative across all three reported periods, with operating losses, net losses, and negative free cash flow (per the SEC financials). Gross, operating, and net margins are each listed as 0% (per market data), and ROIC is -35%. The Roarable RQD rating records an Altman Z-Score of 2.5, a Piotroski F-Score of 2/9, and Debt/Equity of 0.5. Cash was $29.2M at FY 2025 and $26.1M at FY 2024 against continued negative free cash flow. Debt is listed as N/A in the reported periods.
The news wire contains six items, all tagged YELLOW with the impact label "MARKET WIRE":
Risk watch items from the feed are the reported second FDA rejection of the kidney disease NDA (per the Stocktwits headline) and the active securities class action deadline (per the Morningstar item). The feed contains no positive proprietary signals. The Butterfly Supply-Chain Graph lists no supply-chain links and no proprietary signals.
Real-time company headlines, analyst actions, and sector developments for Unicycive Therapeutics Inc. (UNCY) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Unicycive Therapeutics Inc. (UNCY) market action, institutional positioning, and fundamental catalysts.
Morningstar report covering Unicycive Therapeutics Inc. (UNCY) market action, institutional positioning, and fundamental catalysts.
Zacks Investment Research report covering Unicycive Therapeutics Inc. (UNCY) market action, institutional positioning, and fundamental catalysts.
Moomoo report covering Unicycive Therapeutics Inc. (UNCY) market action, institutional positioning, and fundamental catalysts.
Stocktwits report covering Unicycive Therapeutics Inc. (UNCY) market action, institutional positioning, and fundamental catalysts.
The National Law Review report covering Unicycive Therapeutics Inc. (UNCY) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Unicycive Therapeutics Inc. (UNCY) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Unicycive Therapeutics Inc. (UNCY) market action, institutional positioning, and fundamental catalysts.
Welcome to the UNCY (Unicycive Therapeutics Inc.) Roar Pit. Current RQD Composite is 45/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on UNCY, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Unicycive Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on UNCY, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $3.74 (52-wk range $3.35 - $8.74), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).